145 related articles for article (PubMed ID: 34583363)
21. Comparison of efficacy of conbercept, aflibercept, and ranibizumab ophthalmic injection in the treatment of macular edema caused by retinal vein occlusion: a Meta-analysis.
Xing Q; Dai YN; Huang XB; Peng L
Int J Ophthalmol; 2023; 16(7):1145-1154. PubMed ID: 37465496
[TBL] [Abstract][Full Text] [Related]
22. A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN).
Chakravarthy U; Harding SP; Rogers CA; Downes S; Lotery AJ; Dakin HA; Culliford L; Scott LJ; Nash RL; Taylor J; Muldrew A; Sahni J; Wordsworth S; Raftery J; Peto T; Reeves BC
Health Technol Assess; 2015 Oct; 19(78):1-298. PubMed ID: 26445075
[TBL] [Abstract][Full Text] [Related]
23. Short-term results of switchback from aflibercept to ranibizumab in neovascular age-related macular degeneration in clinical practice.
Despreaux R; Cohen SY; Semoun O; Zambrowski O; Jung C; Oubraham H; Souied EH
Graefes Arch Clin Exp Ophthalmol; 2016 Apr; 254(4):639-44. PubMed ID: 26092633
[TBL] [Abstract][Full Text] [Related]
24. Conbercept (KH-902) for the treatment of neovascular age-related macular degeneration.
Nguyen TT; Guymer R
Expert Rev Clin Pharmacol; 2015; 8(5):541-8. PubMed ID: 26289225
[TBL] [Abstract][Full Text] [Related]
25. Twelve-Month Outcomes of Ranibizumab vs. Aflibercept for Neovascular Age-Related Macular Degeneration: Data from an Observational Study.
Gillies MC; Nguyen V; Daien V; Arnold JJ; Morlet N; Barthelmes D
Ophthalmology; 2016 Dec; 123(12):2545-2553. PubMed ID: 27707549
[TBL] [Abstract][Full Text] [Related]
26. Profile of conbercept in the treatment of neovascular age-related macular degeneration.
Lu X; Sun X
Drug Des Devel Ther; 2015; 9():2311-20. PubMed ID: 25960634
[TBL] [Abstract][Full Text] [Related]
27. Treatment Outcomes of Ranibizumab versus Aflibercept for Neovascular Age-Related Macular Degeneration: Data from the Fight Retinal Blindness! Registry.
Bhandari S; Nguyen V; Arnold J; Young S; Banerjee G; Gillies M; Barthelmes D
Ophthalmology; 2020 Mar; 127(3):369-376. PubMed ID: 31757494
[TBL] [Abstract][Full Text] [Related]
28. Pharmacogenomic study on anti-VEGF medicine in treatment of macular Neovascular diseases: a study protocol for a prospective observational study.
Jing J; Yinchen S; Xia C; Jing W; Chong C; Xun X; Hengye H; Kun L
BMC Ophthalmol; 2018 Jul; 18(1):181. PubMed ID: 30041608
[TBL] [Abstract][Full Text] [Related]
29. Anti-Vascular Endothelial Growth Factor Drug Conbercept-Loaded Peptide Hydrogel Reduced Angiogenesis in the Neovascular Age-Related Macular Degeneration.
Fan W; Li S; Tao J; Yu C; Sun M; Xie Z; Wu X; Ge L; Wu Y; Liu Y
J Biomed Nanotechnol; 2022 Jan; 18(1):277-287. PubMed ID: 35180922
[TBL] [Abstract][Full Text] [Related]
30. Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis.
Souied EH; Dugel PU; Ferreira A; Hashmonay R; Lu J; Kelly SP
Ophthalmic Epidemiol; 2016; 23(2):71-9. PubMed ID: 26855278
[TBL] [Abstract][Full Text] [Related]
31. Comparative efficacy and safety of different regimens of ranibizumab for neovascular age-related macular degeneration: a network meta-analysis of randomised controlled trials.
Zhao X; Meng L; Chen Y
BMJ Open; 2021 Feb; 11(2):e040906. PubMed ID: 33550238
[TBL] [Abstract][Full Text] [Related]
32. RANIBIZUMAB AND AFLIBERCEPT FOR THE TREATMENT OF PIGMENT EPITHELIAL DETACHMENT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: Data from an Observational Study.
Vaze A; Nguyen V; Daien V; Arnold JJ; Young SH; Cheung CM; Lamoureux E; Bhargava M; Barthelmes D; Gillies MC;
Retina; 2018 Oct; 38(10):1954-1961. PubMed ID: 28820848
[TBL] [Abstract][Full Text] [Related]
33. Updates on the Management of Ocular Vasculopathies with VEGF Inhibitor Conbercept.
Liu H; Ma Y; Xu HC; Huang LY; Zhai LY; Zhang XR
Curr Eye Res; 2020 Dec; 45(12):1467-1476. PubMed ID: 32631094
[No Abstract] [Full Text] [Related]
34. Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration.
Abouammoh M; Sharma S
Curr Opin Ophthalmol; 2011 May; 22(3):152-8. PubMed ID: 21483262
[TBL] [Abstract][Full Text] [Related]
35. Four-week outcomes of vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration.
Wiryasaputra S; Nguyen V; Arnold JJ; Ferrier R; Hinchcliffe P; Barthelmes D; Gillies MC
Clin Exp Ophthalmol; 2020 Sep; 48(7):946-955. PubMed ID: 32463528
[TBL] [Abstract][Full Text] [Related]
36. Ranibizumab for the treatment of neovascular age-related macular degeneration: a review.
Kourlas H; Abrams P
Clin Ther; 2007 Sep; 29(9):1850-61. PubMed ID: 18035187
[TBL] [Abstract][Full Text] [Related]
37. Comparison of clinical effectiveness of conbercept and ranibizumab for treating retinopathy of prematurity: a meta-analysis.
Jiang S; Li X; Fu M; Huanglu D; Huang J; Huang W; Hu P
Int J Clin Pharm; 2023 Dec; 45(6):1317-1325. PubMed ID: 37204617
[TBL] [Abstract][Full Text] [Related]
38. Bevacizumab versus ranibizumab for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials.
Chen G; Li W; Tzekov R; Jiang F; Mao S; Tong Y
Retina; 2015 Feb; 35(2):187-93. PubMed ID: 25105318
[TBL] [Abstract][Full Text] [Related]
39. Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data.
Korobelnik JF; Delcourt C; Creuzot-Garcher C; Melaine A; Chassetuillier J; Lejeune A; Bénard S; Dupont-Benjamin L
J Med Econ; 2021; 24(1):1087-1097. PubMed ID: 34420480
[TBL] [Abstract][Full Text] [Related]
40. Choroidal Thickness Changes After Intravitreal Ranibizumab for Exudative Age-Related Macular Degeneration.
Minnella AM; Federici M; Falsini B; Barbano L; Gambini G; Lanza A; Caporossi A; Savastano MC
BioDrugs; 2016 Aug; 30(4):353-9. PubMed ID: 27189458
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
